Skip to main content

Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014

Cancer Immunology, Immunotherapy volume 64, pages 923–930 (2015)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Abbreviations

Ab:

Antibody

ACT:

Adoptive cellular transfer

ADCC:

Antibody-dependent cellular cytotoxicity

ATG:

Anti-thymocyte globulin

BTN3A1:

Butyrophilin 3A1

CAR:

Chimeric antigen receptor

CIMT:

Association for Cancer Immunotherapy

CIP:

CIMT Immunoguiding Program

CT:

Cancer–testis

CTLA-4:

Cytotoxic T-lymphocyte-associated protein 4

CTL:

Cytotoxic T lymphocytes

CTX:

Cyclophosphamide

DNAM-1:

DNAX Accessory Molecule-1

FasL:

Fas ligand

IFA:

Incomplete Freud’s adjuvant

IL-10:

Interleukin 10

LP:

Long peptides

PD-1:

Programmed cell death 1

PD-L1:

Programmed death-ligand 1

PGE2:

Prostaglandin E2

RRG:

CIMT Regulatory Research group

SP:

Short peptides

Teff:

T effector cells

TERS:

TCR-engineered reference samples

TIGIT:

T cell immunoreceptor with Ig and ITIM domains

Treg:

T regulatory cells

VEGF-A:

Vascular endothelial growth factor A

Acknowledgments

The authors would like to thank Christiane Wellié-Reeve (Mainz, Germany) for carefully proof reading the meeting report. Selected sessions of the CIMT meeting were made possible by research grants from the German Bundesministerium für Bildung and Forschung (BMBF Grant: 031A018). The CIMT working group CIP receives support for educational activities by the Wallace Coulter Foundation (Florida, USA).

Conflict of interest

The authors declare that they have no conflict of interest. Cedrik M. Britten has been the co-organizer of the meeting. Björn-Philipp Kloke has been the co-organizer of the CIMT Endeavour workshop.

Author information

Authors and Affiliations

  1. BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131, Mainz, Germany

    Björn-Philipp Kloke, Robert A. Jabulowsky & Cedrik M. Britten

  2. Immatics Biotechnologies GmbH, Tübingen, Germany

    Andrea Mahr & Sarah Kutscher

  3. TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany

    Richard Rae & Cedrik M. Britten

Authors
  1. Björn-Philipp Kloke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Mahr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. Jabulowsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarah Kutscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Richard Rae
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cedrik M. Britten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn-Philipp Kloke.

Additional information

This meeting report is a summary of presentations from the Twelfth Annual Meeting of the Association for Cancer Immunotherapy, CIMT 2014, published together with a series of Focussed Research Reviews based on lectures given at the conference.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kloke, BP., Mahr, A., Jabulowsky, R.A. et al. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014. Cancer Immunol Immunother 64, 923–930 (2015). https://doi.org/10.1007/s00262-014-1643-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-014-1643-7

Keywords

  • CIMT 2014
  • Cancer immunotherapy
  • Cancer immunology
  • Tumor vaccination